This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by da Rocha, A. B. Articles by Schwartsmann, G. Search for Related Content PubMed PubMed Citation Articles by da Rocha, A. B. Articles by Schwartsmann, G.

Targeting Protein Kinase C: New Therapeutic Opportunities Against High-Grade Malignant Gliomas?

South-American Office for Anticancer Drug Development (SOAD), Comprehensive Cancer Center, Lutheran University of Brazil, Canoas, RS, Brazil

Correspondence: A. B. da Rocha, Ph.D., South-American Office for Anticancer Drug Development (SOAD), Comprehensive Cancer Center, Lutheran University of Brazil, Rua Miguel Tostes 101, predio 22,5^o andar, 92420 -280 Canoas, RS, Brazil. Telephone:55-51-477-9219; Fax:55-51-478-1747; e-mail: brondani{at}terra.com.br

A large body of evidence suggests that the abnormal phenotype of neoplastic astrocytes, including their excessive proliferation rate and high propensity to invade surrounding tissues, results from mutations in critical genes involved in key cellular events. These genetic alterations can affect cell-surface-associated receptors, elements of signaling pathways, or components of the cell cycle clock, conferring a gain or a loss of relevant metabolic functions of the cells. The understanding of such phenomena may allow the development of more efficacious forms of cancer treatment. Examples are therapies specifically directed against overexpressed epidermal growth factor receptor, hyperactive Ras, excessively stimulated Raf-1, overproduced ornithine decarboxylase, or aberrantly activated cyclin-dependent kinases. The applicability of some of these approaches is now being assessed in patients suffering from primary malignant central nervous system tumors that are not amenable to current therapeutic modalities. Another potentially useful therapeutic strategy against such tumors involves the inhibition of hyperactive or overexpressed protein kinase C (PKC). This strategy is justified by the decrease in cell proliferation and invasion following inhibition of the activity of this enzyme observed in preclinical glioma models. Thus, interference with PKC activity may represent a novel form of experimental cancer treatment that may simultaneously restrain the hyperproliferative state and the invasive capacity of high-grade malignant gliomas without inducing the expected toxicity of classical cytotoxic agents. Of note, the experimental use of PKC-inhibiting agents in patients with refractory high-grade malignant gliomas has indeed led to some clinical responses. The present paper reviews the current status of the biochemistry and molecular biology of PKC, as well as the possibilities for developing novel anti-PKC-based therapies for central nervous system malignancies.

Key Words. Protein kinase C • High-grade malignant gliomas • Intracellular signaling • Mitogen-activated protein kinase/extracellular-signal-regulated kinase • Extracellular-signal-regulated kinases • Ornithine decarboxylase • Cell proliferation • Cell invasion

This article has been cited by other articles:

				T. N. Kreisl, L. Kim, K. Moore, P. Duic, S. Kotliarova, J. Walling, L. Musib, D. Thornton, P. S. Albert, and H. A. Fine A Phase I Trial of Enzastaurin in Patients with Recurrent Gliomas Clin. Cancer Res., May 15, 2009; 15(10): 3617 - 3623. [Abstract] [Full Text] [PDF]

				K.-W. Lee, S. G. Kim, H.-P. Kim, E. Kwon, J. You, H.-J. Choi, J.-H. Park, B.-C. Kang, S.-A. Im, T.-Y. Kim, et al. Enzastaurin, a Protein Kinase C{beta} Inhibitor, Suppresses Signaling through the Ribosomal S6 Kinase and Bad Pathways and Induces Apoptosis in Human Gastric Cancer Cells Cancer Res., March 15, 2008; 68(6): 1916 - 1926. [Abstract] [Full Text] [PDF]

				J.-A. Park, A. L. Crews, W. R. Lampe, S. Fang, J. Park, and K. B. Adler Protein Kinase C{delta} Regulates Airway Mucin Secretion via Phosphorylation of MARCKS Protein Am. J. Pathol., December 1, 2007; 171(6): 1822 - 1830. [Abstract] [Full Text] [PDF]

				S. Amos, M. Mut, C. G. diPierro, J. E. Carpenter, A. Xiao, Z. A. Kohutek, G. T. Redpath, Y. Zhao, J. Wang, M. E. Shaffrey, et al. Protein Kinase C-{alpha} Mediated Regulation of Low-Density Lipoprotein Receptor Related Protein and Urokinase Increases Astrocytoma Invasion Cancer Res., November 1, 2007; 67(21): 10241 - 10251. [Abstract] [Full Text] [PDF]

				T. A. DeVries-Seimon, A. M. Ohm, M. J. Humphries, and M. E. Reyland Induction of Apoptosis Is Driven by Nuclear Retention of Protein Kinase C{delta} J. Biol. Chem., August 3, 2007; 282(31): 22307 - 22314. [Abstract] [Full Text] [PDF]

				K. Podar, M. S. Raab, J. Zhang, D. McMillin, I. Breitkreutz, Y.-T. Tai, B. K. Lin, N. Munshi, T. Hideshima, D. Chauhan, et al. Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl) Blood, February 15, 2007; 109(4): 1669 - 1677. [Abstract] [Full Text] [PDF]

				J. R. Slupsky, A. S. Kamiguti, R. J. Harris, J. C. Cawley, and M. Zuzel Central Role of Protein Kinase C{epsilon} in Constitutive Activation of ERK1/2 and Rac1 in the Malignant Cells of Hairy Cell Leukemia Am. J. Pathol., February 1, 2007; 170(2): 745 - 754. [Abstract] [Full Text] [PDF]

				E. P. Jane, D. R. Premkumar, and I. F. Pollack Coadministration of Sorafenib with Rottlerin Potently Inhibits Cell Proliferation and Migration in Human Malignant Glioma Cells J. Pharmacol. Exp. Ther., December 1, 2006; 319(3): 1070 - 1080. [Abstract] [Full Text] [PDF]

				M. A. Carducci, L. Musib, M. S. Kies, R. Pili, M. Truong, J. R. Brahmer, P. Cole, R. Sullivan, J. Riddle, J. Schmidt, et al. Phase I Dose Escalation and Pharmacokinetic Study of Enzastaurin, an Oral Protein Kinase C Beta Inhibitor, in Patients With Advanced Cancer J. Clin. Oncol., September 1, 2006; 24(25): 4092 - 4099. [Abstract] [Full Text] [PDF]

				V. D. Dixit, A. T. Weeraratna, H. Yang, D. Bertak, A. Cooper-Jenkins, G. J. Riggins, C. G. Eberhart, and D. D. Taub Ghrelin and the Growth Hormone Secretagogue Receptor Constitute a Novel Autocrine Pathway in Astrocytoma Motility J. Biol. Chem., June 16, 2006; 281(24): 16681 - 16690. [Abstract] [Full Text] [PDF]

				M. Saleem, S. Kaur, M.-H. Kweon, V. M. Adhami, F. Afaq, and H. Mukhtar Lupeol, a fruit and vegetable based triterpene, induces apoptotic death of human pancreatic adenocarcinoma cells via inhibition of Ras signaling pathway Carcinogenesis, November 1, 2005; 26(11): 1956 - 1964. [Abstract] [Full Text] [PDF]

				J. R. Graff, A. M. McNulty, K. R. Hanna, B. W. Konicek, R. L. Lynch, S. N. Bailey, C. Banks, A. Capen, R. Goode, J. E. Lewis, et al. The Protein Kinase C{beta}-Selective Inhibitor, Enzastaurin (LY317615.HCl), Suppresses Signaling through the AKT Pathway, Induces Apoptosis, and Suppresses Growth of Human Colon Cancer and Glioblastoma Xenografts Cancer Res., August 15, 2005; 65(16): 7462 - 7469. [Abstract] [Full Text] [PDF]

				J. Koivunen, V. Aaltonen, S. Koskela, P. Lehenkari, M. Laato, and J. Peltonen Protein Kinase C {alpha}/{beta} Inhibitor Go6976 Promotes Formation of Cell Junctions and Inhibits Invasion of Urinary Bladder Carcinoma Cells Cancer Res., August 15, 2004; 64(16): 5693 - 5701. [Abstract] [Full Text] [PDF]

				M. D. Rochdi and J.-L. Parent Galpha q-coupled Receptor Internalization Specifically Induced by Galpha q Signaling. REGULATION BY EBP50 J. Biol. Chem., May 9, 2003; 278(20): 17827 - 17837. [Abstract] [Full Text] [PDF]

				T. T. Su, B. Guo, and D. J. Rawlings Emerging Roles for PKC Isoforms in Immune Cell Function Mol. Interv., June 1, 2002; 2(3): 141 - 144. [Abstract] [Full Text]